anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
In addition to the warnings listed above, the following syndromes and serious reactions have been reported in patients on Dapsone.

Hematologic Effects: Dose-related hemolysis is the most common adverse effect and is seen in patients with or without G6PD deficiency. Almost all patients demonstrate the inter-related changes of a loss of 1 to 2g of hemoglobin, an increase in the reticulocytes (2 to 12%), a shortened red cell life span and a rise in methemoglobin. G6PD deficient patients have greater responses.

Nervous System Effects: Peripheral neuropathy is a definite but unusual complication of Dapsone therapy in non-leprosy patients. Motor loss is predominant. If muscle weakness appears, Dapsone should be withdrawn. Recovery on withdrawal is usually substantially complete. The mechanism of recovery is reported by axonal regeneration. Some recovered patients have tolerated retreatment at reduced dosage. In leprosy this complication may be difficult to distinguish from a leprosy reactional state. 

Body As A Whole: In addition to the warnings and adverse effects reported above, additional adverse reactions include: nausea, vomiting, abdominal pains, pancreatitis, vertigo, blurred vision, tinnitus, insomnia, fever, headache, psychosis, phototoxicity, pulmonary eosinophilia, tachycardia, albuminuria, the nephrotic syndrome, hypoalbuminemia without proteinuria, renal papillary necrosis, male infertility, drug-induced Lupus erythematosus and an infectious mononucleosis-like syndrome. In general, with the exception of the complications of severe anoxia from overdosage (retinal and optic nerve damage, etc.) these adverse reactions have regressed off drug.
This is a phase 2, open-label, non-randomized, single-arm study in patients with high-risk PCa diagnosed with prostate biopsy and undergoing RP and ePLND. Screening assessments should be performed no more than 3 weeks prior to the start of study treatment. Local, nodal and systemic staging with prostate mpMRI, abdominal and chest CT, PSMA-PET/CT and bone scans will be performed before the administration of pembrolizumab. Pembrolizumab will be administered at the dose of 200 mg intravenously, every 3 weeks, for a total of 3 cycles prior to RP and ePLND. Following the screening assessment, subsequent assessments will be carried out after the 3 administrations of the study drug prior to RP and ePLND. If an unscheduled assessment is performed and the patient has not progressed, the results should be reported at the next scheduled visit. After the last cycle of pembrolizumab, mpMRI and PSMA-PET/CT scan will be performed to re-stage the tumour. Progressive disease will be defined as an increase of 20% in the maximum diameter of the index lesion at multiparametric MRI or as the onset of nodal or distant metastases at imaging or onset of symptoms and skeletal related events. In the case of symptomatic disease progression (i.e., de novo onset of symptomatic distant metastases), the patient will not complete the 3 cycles of pembrolizumab and will be considered for immediate imaging (i.e., bone scan, mpMRI and PSMA-PET/CT scan) to re-stage the tumour and for treatment according to clinical guidelines. After RP, patients will be managed according to clinical guidelines. PDL-1 status will be assessed on all samples of patients enrolled on the study. Tissue and blood samples will be collected before and after the administration of pembrolizumab. The presence of biomarkers predictive of radiological and pathological response to neoadjuvant administration of pembrolizumab will be assessed. Patients will be monitored carefully for the development of adverse events and will be monitored for clinical evidence of disease progression according to usual standards of clinical practice. Adverse events will be evaluated according to criteria outlined in the NCI Common Terminology Criteria for Adverse Events (CTCAE), version 4.03. There will be no intrapatient dose escalation in this study. For individual patients that experience dose-limiting toxicities, no criteria for dose modification of pembrolizumab will be applied, but only criteria for dose delays as detailed in the protocol. Patients will be treated with a maximum of 3 cycles of therapy until surgery (i.e. RP and ePLND), provided that no dose-limiting toxicities will occur throughout the treatment course for each individual patient.
BACKGROUND: Despite a significant declined in malaria incidence in Thailand, the rising global travel has resulted in an increase of imported malaria cases, posing a threat to the goal of malaria elimination. This study aims to understand the epidemiological trends and clinical outcomes of imported malaria cases in Thailand.
METHODS: Medical records of all imported malaria cases admitted from 1st January 2013 to 31st December 2022 at the Hospital for Tropical Diseases, Thailand, were retrospectively examined. Demographic data, travel details, severity of illness, and clinical outcomes were described. Logistic regression was performed to identify factors associated with severe disease outcomes.
RESULTS: In total, 335 cases of imported malaria were identified, with 33 % classified as transnational malaria and 67 % as border malaria. Transnational malaria cases (79 % P. falciparum) were mostly acquired from Sub-Saharan Africa for business or visiting friends and relatives (VFRs). Border malaria cases (81 % P. vivax) involved unskilled labourers and were acquired from land-border countries. The proportion of imported malaria in business travelers increased from 13 % to 50 % over the ten years. Risk factors for severe imported malaria included male gender, age 40 and older, infection with P. falciparum, and acquired malaria from Africa.
CONCLUSIONS: Understanding unique demographic and socioeconomic characteristics in both border and transnational cases is crucial for effective malaria prevention. The increasing imported malaria among business travelers highlight the need for targeted prevention in this high-risk group.
This group contains patients who are not randomized and have given informed consent undergo treatment with radioactive iodine (I-131) according to local standard (e.g. fixed dose or dose-calculation based on iodine uptake and thyroid nodule mass).
Each patient's oxygen saturation will be measured non-invasively via a nondisposable polyethylene neonatal probe taped to the infant's palm, toe, or dorsum of the foot. The probe will be connected to an Massimo Rad97 pulse oximeter that is standardized at the factory. It runs through an automatic systems check when turned on and needs no further calibration before being used. The oxygen saturation measurements will be considered valid when there will be a normal plethysmographic waveform, a fullscale signal strength bar, and a stable heart rate closely approximating an independent electrocardiographic (ECG) pulse rate. The pulse oximeter works by using the technology of plethsmography which allows the detection of an arterial pulse) with oximetry (which measures oxygen saturation at specific wavelengths). The pulse oximeter will be placed on each infant as already described. After a stable pulse oximeter reading was obtained, the value will be recorded ("before") and then the probe will be covered with a standard disposable diaper, shiny side up. When the reading stabilized, the value will be recorded ("during") and then the diaper will be removed.
The present invention relates to medicine for treating dermatosis and a preparation method thereof, which is characterized in that the medicine is prepared from the following raw materials of weight compounding ratios: Kunming mountain begonia, sweet wormwood herb, baical skullcap root, cortex dictamni radices, red sage root, rhizoma corydalis, pinellia tuber, dodder seed and licorice root. The medicine has better curative effect on treating various kinds of dermatosis relevant to immunity, wherein the curative effect of the medicine for treating actinic dermatosis and aseptic pustulosis is particularly better, and the effective rate is more than 82%. The toxicity of the compound Kunming mountain begonia medicine of the present invention is lower than that of a single Kunming mountain begonia preparation, and thus, the medicine has more safety. The mechanism of action of the medicine is characterized in that the secretion of IFN-gamma is inhibited so as to down regulate the expression of ICAM-1, inhibit the activation of T lymphocyte and reduce the chemotaxis of the T lymphocyte and the generation of inflammatory factors, and thus, the infiltration of partial monocyte is reduced, which has the effects of inflammation resistance and immunity regulation. Compared with the single Kunming mountain begonia preparation, the compound Kunming mountain begonia medicine has stronger effect of resisting mouse photoallergy. The present invention not only has better curative effect on treating dermatosis, but also can reduce the toxicity of Kuming mountain begonia and enhance the effects of resisting inflammation and regulating immunity, and thus, the medicine has better clinical use value.
PURPOSE:To obtain a skin drug for external use, containing a specific lipid derivative and surfactant and capable of enhancing water holding power of a keratinous layer and improving roughening of the skin. CONSTITUTION:A medicinal skin drug for external use or cosmetic (e.g. cream, milky lotion, toilet water, lipstick, foundation or hairdressing) containing a lipid derivative expressed by formula I [R1 is 10-26C alkyl; R2 is 9-25C alkyl; X and Y are H or phosphoric acid ester group expressed by formula II (R3-R5 are H, 1-6C alkyl or aralkyl), provided that X and Y are not H at the same time]. The amount of the blended compound expressed by formula I is preferably 0.1-20wt.% based on the total composition in the case of an emulsion type agent and 5-25wt.% in the case of an oily agent containing a liquid hydrocarbon as a base. The surfactant has action on enhancement of effects and a glyceryl ether expressed by formula III [R6 is 8-24C alkyl, especially preferably a group expressed by formula IV (p is 4-10; q is 5-11)] is preferred. The amount thereof blended is 0.1-5wt.% based on the total composition.
Cognitive impairment is prevalent, disabling, and poorly-managed among the 1 million Americans living with multiple sclerosis (MS). Indeed, 67% of adults with MS have cognitive impairment, particularly slowed cognitive processing speed (CPS), and this is associated with impaired learning and memory and worse fatigue, depression, anxiety, pain, and quality of life (QOL). This underscores the importance of identifying efficacious approaches for managing CPS impairment and its consequences among those with MS. There is merit in a remotely-delivered physical activity (PA) intervention for managing MS-related CPS dysfunction in MS. We have provided evidence from a pilot, randomized controlled trial (RCT) that an Internet-delivered PA intervention resulted in a clinically meaningful improvement in CPS among those with mild MS-related ambulatory disability; there were additional improvements in fatigue, depression, anxiety, pain, and QOL. The pilot RCT did not a priori recruit persons with MS who had objective CPS impairment nor examine sustainability of CPS changes over time, and it involved a waitlist control that did not account for the effects of attention and social contact. We leverage our experiences and preliminary results, and propose an appropriately-powered, Phase-II, RCT of a highly-developed and refined Internet-delivered PA intervention focusing on walking during ambulatory activities of daily living (steps/day) for yielding immediate and sustained improvements in remotely-assessed CPS among persons with mild MS-related ambulatory disability who demonstrate impaired CPS. The proposed study, if successful, will provide Class I evidence regarding the efficacy of a 6-month, Internet-delivered, PA intervention compared with an active control condition for improving important outcomes in 300 adults with MS who present with both mild MS ambulatory disability and impaired CPS. The primary outcome is the remotely-delivered Symbol Digit Modalities Test as a measure of CPS; the secondary outcomes include a remotely-delivered, objective measure of learning and memory and self-reports of fatigue, depression, anxiety, pain, and QOL; the tertiary outcome is accelerometry as an objective, device-based measure of PA. The conditions will be delivered by persons who are uninvolved in screening, recruitment, random assignment, and outcome assessment. We will collect outcomes on 3 occasions over a 12-month period (i.e., pre-intervention, immediately post-intervention, and 6-month follow-up). The outcomes will be collected using a blinded assessor. Data analyses will involve intent-to-treat principles, and mixed-effects models and logistic regression. The proposed research may yield "real-world" guidelines for free-living PA change that can be implemented for the treatment of CPS impairment in MS. Such an opportunity for rehabilitation of cognitive function using an approach with broad reach and scalability is paramount considering the prevalent, disabling, and poorly-managed nature of CPS impairment in MS and limited resources for its treatment.
PURPOSE:To obtain a photochromic titanium oxide compd. capable of being put to practical use by blending a titanium compd. with a specified amt. of a metal compd. imparting photochromic property and a specified amt. of a sodium compd. CONSTITUTION:A titanium compd. is blended with 0.1-1.0wt.% (expressed in terms of sodium oxide) sodium compd. and 0.2-8.0wt.% (expressed in terms of metal oxide) metal compd. of at least one among iron, chromium, copper, nickel, vanadium and manganese so that the total amt. is regulated to 100wt.% (expressed in terms of oxides).
The invention provides isolated anti-ovarian, pancreatic, lung or breast cancer antigen (Ovr115) antibodies that bind to Ovr115 on a mammalian cell in vivo. The invention also encompasses compositions comprising an anti-Ovr115 antibody and a carrier. These compositions can be provided in an article of manufacture or a kit. Another aspect of the invention is an isolated nucleic acid encoding an anti-Ovr115 antibody, as well as an expression vector comprising the isolated nucleic acid. Also provided are cells that produce the anti-Ovr115 antibodies. The invention encompasses a method of producing the anti-Ovr115 antibodies. Other aspects of the invention are a method of killing an Ovrl 15-expressing cancer cell, comprising contacting the cancer cell with an anti~-Ovr115 antibody and a method of alleviating or treating an Ovrl 15-expressing cancer in a mammal, comprising administering a therapeutically effective amount of the anti-Ovr115 antibody to the mammal.
Provided are compositions and methods for activating latent Human Immunodeficiency Virus (HIV). The compositions and methods may utilize a recombinant peptide that has a DNA binding zinc finger domain specific to the HIV long terminal repeat (LTR) sequence. The recombinant peptide may also have a transcription factor (e.g. a transcription activator) that is conjugated to the zinc finger domain. Also provided are methods of treating HIV in a subject in need of the treatment. The method may involve activation of latent HIV in cells of the subject and selectively removing such cells from the subject, providing complete and effective treatment of HIV.
Pts were instructed to train at least 5 times/ week in the inpatient setting. After discharge pts were instructed to train in a home-based setting at least 3 times/week for a period of 8 weeks.
Cervical cancer (CC) is the fourth most common cancer affecting women worldwide. The risk of women immunosuppressed due to AIDS or organ transplantation is well documented, as most cases are caused by persistent human papillomavirus (HPV) infection and immunosuppression can prevent clearing HPV. Although European guidelines advise that inflammatory bowel disease (IBD) women under immunosuppression should be screened for CC as regularly as high-risk patients, quality evidence is lacking in our country. We performed a retrospective case-control (2020-2021) study to analyse the risk factors associated with the appearance of low-grade (LSIL) or high-grade (HSIL) squamous intraepithelial cervical lesions in patients with IBD. We included all women aged 21-65 years , followed up at the University Hospital Fundación Alcorcón (Spain). Cases were defined as those patients with abnormalities in cervical cytology, while the control group consisted of the rest of the women. Disease characteristics, treatments and epidemiological data (smoking habit, sexual behaviour and reproductive history) were obtained. We documented the evolution of abnormalities over time and compare data between women under immunosuppressive treatment or not.
The present invention relates to a 'Liuwei digestion stabilizing preparation' for treating gastralgia, gasteremphraxis, dyspepsia, astriction and dysmenorrhea, which belongs to a traditional Chinese medicine preparation for enhancing gastric motility. The preparation of the present invention is prepared from raw materials, such as elecampane, rhubarb, galanga resurrectionlily rhizome, calcined gypsum lamelliforme, fructus chebulae and trona through the modern advanced technology methods, such as a penetrating method, a concentrating method, a drying method, etc. The medicinal preparation of the present invention overcomes the disadvantages that in the 'original Liuwei digestion stabilizing capsule' preparation, because the production technology is coarse, finished product bacteria and heavy metals are easy to exceed standard, the dosage is large, the dependence of patients is poor, etc. The present invention also relates to a preparation method of the medicinal preparation of the present invention. Compared with the 'original Liuwei digestion stabilizing capsule' preparation, the present invention has the advantages that the dosage is reduced half, and the quality standard is further perfected and improved. The pharmacodynamics research indicates that the medicinal preparation of the present invention has the functions of enhancing the gastric motility of a mouse, alleviating pain, protecting the gastric mucosa of a rat and promoting the gastric secretion of the rat.
Neuromyelitis Optica Spectrum Disorder (NMOSD) is an immune-mediated neuroinflammatory disease of the central nervous system. Patients typically present with sensory deficits, weakness, and incontinence. This is a case of a 43-year-old female with diabetes mellitus admitted for acute onset leg weakness and stool incontinence. Spinal MRI imaging revealed transverse myelitis, and her lab work was significant for an anti-aquaporin 4 (AQP4) antibody titer of 1:2,560. Initial treatment consisted of a high-dose steroid taper and plasmapheresis. This unique case illustrates the importance in recognizing delayed presentations of rare neuroinflammatory conditions previously assumed to be a sequela of diabetic neuropathy.
Permanent cardiac pacing is the most efficient treatment for various conduction disorders, including high-degree atrioventricular block and symptomatic sick sinus syndrome. High-burden right ventricular (RV) pacing is often tolerated for decades without overt left ventricular (LV) failure in most patients. It has been shown, however, that prolonged RV pacing reduces LV function and ultimately causes heart failure. Left ventricular ejection fraction (LVEF) may decrease in specific individuals with pacemaker implants following pacing, which is called Pacing-induced cardiomyopathy (PICM). However, pacing-induced LV dysfunction (PIVD) at milder severity levels has also been documented.RV apical pacing, the classic site for pacemaker lead implantation, results in ventricular dys-synchrony and deterioration of left ventricular (LV) function and ejection fraction, like left bundle branch block. Recently, alternative sites are arising, such as right ventricular outflow tract (RVOT) and the septum. Studies show that deformation imaging by speckle tracking echocardiography following pacemaker implantation can predict the patients at higher risk for PCIM and PIVD at long-term follow-up. Deformation imaging, or strain imaging, provides unique Information on regional and global ventricular function. Global longitudinal strain is Known to be more precise than ejection Fraction. It is now used in patients with heart failure, ischemic heart disease, and Receiving chemotherapy to detect early Changes in cardiac function before changes in ejection fraction. Speckle tracking Echocardiography for strain measurement Depends on tracking of speckles throughout the Cardiac cycle in apical 4,3, and 2 chamber Views. The software allows the elaboration of myocardial deformation in 3 spatial directions: Longitudinal, radial, and circumferential. Predicting PICM and PIVD 6 months after pacemaker implantation is possible by measuring global longitudinal strain (GLS) baseline one and six months after implantation.
Acitretin, commonly used for severe psoriasis and keratinocyte carcinoma chemoprevention in high-risk patients, is contraindicated in patients with end-stage renal disease (ESRD) on haemodialysis (HD). However, these patients often lack medication choices and in certain clinical scenarios the benefits of acitretin may outweigh the potential risks. We identified 24 patients with ESRD on HD undergoing acitretin treatment from the Duke and Vanderbilt University Medical Centers. While adverse effects were common, they were not a frequent cause of treatment discontinuation among patients. We also found no association between acitretin treatment and hospital admissions or mortality. Lastly, we found statistically significant increases in alkaline phosphatase (ALP; P = 0.03) and total bilirubin (P < 0.001) when patients were receiving acitretin and HD compared with baseline. However, there was no dose dependency or temporal association with acitretin or HD initiation. Based on these preliminary findings, we find that acitretin may safely be used in patients receiving HD, with close monitoring of ALP and bilirubin.